SanegeneBio and Orbit join forces to establish targeting peptides
Agreement covers cell-based studies, with an additional option to further develop screening activities - News - PharmaTimes
Stay updated with breaking news from Neil Butt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agreement covers cell-based studies, with an additional option to further develop screening activities - News - PharmaTimes
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc.
Biopharmaceutical company Orbit Discovery has been awarded a £472,000 Smart grant by Innovate UK, to facilitate the implementation of droplet-based microfluidics for cell-based functional screening to advance the discovery of peptide therapeutic candidates. Click to read more...
Peptide technology company Orbit Discovery has announced a partnership with WuXi AppTec that will see the combination of its peptide discovery platform and experience with the Chinese organisation’s downstream capabilities as a leading global provider of R&D and manufacturing services provision for the pharmaceutical and healthcare industry. Click to read more...
WuXi AppTec’s development and manufacturing platform will enable Orbit to generate peptides at small or large scale